Skip to content
Question
What will a month cost?
Read
7 min
Published
September 2026

GHK-Cu Peptide Injection: The Route No Compounding List Covers

Federal law leaves the injectable route off both compounding lists by name, FDA has published its reason, and no study has dosed a person that way. What the lawful topical form costs instead, computed from every seller that publishes a price.

ByDerek MossPricing analystPublished

GHK-Cu by injection carries no price here. The lawful forms do: a typical $134 a month for the topical, across 34 sellers. The reason is a route exclusion written into the federal list. It is worth reading in full.

180

PubMed records for GHK-Cu

Source: PubMed, searched September 2026

0

Human studies dosing it by injection

Source: PubMed, humans filter plus an injected route

2

Tracked sellers advertising the shot

Source: Computed from every tracked seller

What the two federal lists actually say

The 503A list carries the entry “GHK-Cu (except for injectable routes of administration)” in Category 1[1]. The parenthesis is the whole answer.

That wording arrived by a specific route. FDA took GHK-Cu off Category 1 on April 22, 2026, because the nominations were withdrawn[1].

One nominator wrote back on May 5, 2026. It had meant to withdraw only the injectable route[1]. The non-injectable entry went back on the list[1].

The outsourcing-facility list is the other door, and it is shut too. The 503B categories, updated March 21, 2025, name no form of GHK-Cu or copper tripeptide anywhere[2].

A 503A pharmacy has an interim policy covering the non-injectable routes only. A 503B facility has no listed route at all. The split is set out in 503A vs 503B.

FDA's stated reason for the exclusion

FDA files GHK-Cu for injectable routes under bulk substances nominated but withdrawn[3]. It gives a reason there.

Compounded injectable GHK-Cu may pose a risk of immunogenicity, from aggregation and peptide-related impurities[3]. Human data are limited[3].

Category 1 is not an approval either. It is an evaluation, and FDA says so in its own interim policy[4]. The agency does not intend to act against compounding from a Category 1 substance while that evaluation runs[4].

Sellers advertise the shot anyway

Of the 79 tracked sellers carrying GHK-Cu, 2 publish an injectable product. Those prices are held out of every figure on this site.

The rule is mechanical, not editorial. The compound register scopes GHK-Cu to non-injectable routes, and each price is gated on that scope before it can count.

One consequence is worth naming. A quote for an injectable vial cannot be compared with the board, because the board prices a different product.

What the lawful forms cost

Compounded GHK-Cu, per month, by route, September 2026
TopicalSwallowedUnder the tongueInjection
Sellers publishing a month34No marketNo marketNot priced here
Lowest published month$69No marketNo marketNot priced here
Typical (median) month$134No marketNo marketNot priced here
Highest published month$209No marketNo marketNot priced here
Compounded GHK-Cu, per month, by route, September 2026. Computed from every tracked seller publishing a monthly figure for that route, each counted once at its lowest month. A route with fewer than three such sellers has no market. The injectable route is on no federal compounding list, so no price for it is published here.

Only the topical route has enough priced sellers for a market. The swallowed and sublingual products exist, but at two or three sellers a figure is a coincidence, not a price.

A jar is also not a month. Turning a container into a monthly figure is worked through in GHK-Cu cost. The cosmetic version of the same product is priced in copper peptide serum.

What the published record contains

GHK is a three-amino-acid sequence found in human plasma, saliva and urine, and it declines with age[5]. It is proposed to act as a complex with copper[5].

That review comes from a skincare company’s own research department, which is worth knowing when reading its claims[5].

A 2026 sports-medicine review places GHK-Cu among peptides sold direct to patients outside the approval process[6]. Its summary of that whole group is that rigorous human safety data are scarce[6].

The search record is the plainer answer. PubMed indexes 180 GHK-Cu records. Twenty mention an injected route. Three are randomized trials, and all three applied it to the skin or tested it in animals.

Restrict the search to human studies using a subcutaneous, intravenous or intramuscular route and nothing comes back at all.

Three questions before paying for a vial

  • Which route is the product, and does the pharmacy name its compounding category?
  • What is the concentration, and how many days does one container last at the stated use?
  • Does the quoted price include the consult, and what does month two cost?

The last one moves the bill most. Fees outside the headline price are listed in peptide therapy cost. The wider buying question is covered in where to get peptides.

FAQ

5 questions

Can a pharmacy legally compound a GHK-Cu injection in the United States?

No federal list covers it. The 503A bulk substances list carries GHK-Cu only in the form "GHK-Cu (except for injectable routes of administration)", and the 503B categories for outsourcing facilities name no form of GHK-Cu at all.

Why does this site publish no price for a GHK-Cu injection?

The compound register scopes GHK-Cu to topical, nasal, oral and sublingual routes, and every price is gated on that scope before it can count. Injectable listings exist among tracked sellers, and they are held out of every computed figure here.

What has FDA said about injecting GHK-Cu?

FDA lists GHK-Cu for injectable routes among bulk substances nominated but withdrawn, and states that compounded injectable drugs containing it may pose a risk of immunogenicity from aggregation and peptide-related impurities, with limited data in humans.

Is there human research on injected GHK-Cu?

A PubMed search finds 180 GHK-Cu records, of which twenty mention an injected route and three are randomized trials, all of them topical or in animals. Restricting the search to human studies using a subcutaneous, intravenous or intramuscular route returns nothing.

Could the rule change?

The 503A list states that FDA intends to consult the Pharmacy Compounding Advisory Committee before the end of February 2027 about including GHK-Cu on the 503A bulks list. A committee vote is a recommendation and changes nothing until a final rule does.

Sources

6 cited
  1. [1]Food and Drug Administration (2026). Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026) U.S. Food and Drug Administration. Source
  2. [2]Food and Drug Administration (2025). Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act (updated March 21, 2025) U.S. Food and Drug Administration. Source
  3. [3]Food and Drug Administration (2026). Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks U.S. Food and Drug Administration. Source
  4. [4]Food and Drug Administration (2019). Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry U.S. Food and Drug Administration. Source
  5. [5]Pickart L, Vasquez-Soltero JM, Margolina A (2015). GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration BioMed Research International. PMID 26236730
  6. [6]Mendias CL, Awan TM (2026). Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance Sports Medicine. PMID 41966639